

CORCEPT THERAPEUTICS INC  
Form 8-K  
March 28, 2007

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934.

**Date of Report: March 22, 2007**  
**(Date of earliest event reported)**

**Corcept Therapeutics Incorporated**  
**(Exact name of registrant as specified in its charter)**

**CA**  
**(State or other jurisdiction**  
**of incorporation) 000-50679**

**(Commission File Number) 77-0487658**  
**(IRS Employer**

**Identification Number)**

**149 Commonwealth Drive**  
**(Address of principal executive offices) 94025**

**(Zip Code)**  
**650-327-3270**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

(b) On March 22, 2007, Fred Kurland, the Company's Chief Financial Officer tendered his resignation effective April 13, 2007. On March 28, 2007, Anne M. LeDoux was appointed Vice President and Controller and Chief Accounting Officer.

**Item 9.01. Financial Statements and Exhibits**

**(a) Financial statements:**

None

**(b) Pro forma financial information:**

None

**(c) Shell company transactions:**

None

**(d) Exhibits**

99.1 Press Release of Corcept Therapeutics Incorporated dated March 28, 2007

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 28, 2007

**CORCEPT THERAPEUTICS INCORPORATED**

By: /s/ Joseph K. Belanoff

Joseph K. Belanoff

*Chief Executive Officer*

---

**Exhibit Index** **Exhibit No. Description** 99.1 Press Release of Corcept Therapeutics Incorporated dated March 28, 2007